Healthcare has been one of the toughest sectors for investors over the past year. In fact, over the last 12 months, it has been the worst performing sector in the entire market. Many of the industry’s former high-flyers, like Eli Lilly ((LLY), whose GLP-1 drugs have been hailed as breakthrough treatments for diabetes and obesity, have faced steep corrections.But with sentiment now near rock-bottom and valuations reset, the sector may be offering a rare entry point. I see a particularly compelling setup for ...